Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Buy" by Analysts

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus rating of “Buy” from the ten analysts that are covering the stock, MarketBeat reports. Ten analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […]

Related Keywords

United States , Piper Sandler , Iovance Biotherapeutics , Avoro Capital Advisors , Goldman Sachs Group , Nasdaq , Barclays , Iovance Biotherapeutics Inc , Artisan Partners Limited Partnership , Vanguard Group Inc , Wells Fargo Company , Pricet Rowe Associates Inc , Get Free Report , Wells Fargo , Capital Advisors , Partners Limited Partnership , Get Free ,